Promising peer-reviewed results published in Psychopharmacology
On September 8, 2018, the results of the first clinical trial of MDMA-assisted psychotherapy for the treatment of social anxiety were published in the peer-reviewed journal Psychopharmacology. All 12 participants in the small pilot study were adults on the autism spectrum, a population that commonly experiences severe social anxiety.
Sponsored by the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS), the study found significant and lasting reductions in social anxiety following two sessions of MDMA-assisted psychotherapy along with additional preparatory and integrative sessions without MDMA. The study also demonstrated the safety of limited doses of MDMA in a controlled therapeutic setting. In this study, MDMA-assisted psychotherapy was not intended to treat autism itself, but rather for social anxiety in autistic adults.
For additional details, you may review these resources: